| 000 | 01826 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517184952.0 | ||
| 264 | 0 | _c20190409 | |
| 008 | 201904s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1002/cpt.911 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAmstutz, Ursula | |
| 245 | 0 | 0 |
_aClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _c02 2018 |
||
| 300 |
_a210-216 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Practice Guideline; Systematic Review | ||
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aCapecitabine _xadministration & dosage |
| 650 | 0 | 4 | _aClinical Decision-Making |
| 650 | 0 | 4 |
_aDihydrouracil Dehydrogenase (NADP) _xgenetics |
| 650 | 0 | 4 | _aDrug Dosage Calculations |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aPharmacogenetics _xstandards |
| 650 | 0 | 4 |
_aPharmacogenomic Testing _xstandards |
| 650 | 0 | 4 | _aPharmacogenomic Variants |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aPrecision Medicine _xstandards |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 700 | 1 | _aHenricks, Linda M | |
| 700 | 1 | _aOffer, Steven M | |
| 700 | 1 | _aBarbarino, Julia | |
| 700 | 1 | _aSchellens, Jan H M | |
| 700 | 1 | _aSwen, Jesse J | |
| 700 | 1 | _aKlein, Teri E | |
| 700 | 1 | _aMcLeod, Howard L | |
| 700 | 1 | _aCaudle, Kelly E | |
| 700 | 1 | _aDiasio, Robert B | |
| 700 | 1 | _aSchwab, Matthias | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 103 _gno. 2 _gp. 210-216 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpt.911 _zAvailable from publisher's website |
| 999 |
_c27802807 _d27802807 |
||